Tolvaptan Intervention study and Genetic mutation of Autosomal Dominant Polycystic Kidney Disease

Tolvaptan Intervention study to Autosomal Dominant Polycystic Kidney Disease patients without Genetic mutation of disease gene - TIAG

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180259

Enrollment

Registered

2019-03-14

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADPKD

Interventions

Tolvaptan treatment

Tolvaptan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ADPKD patients without genetic mutation of disease gene(PKD1, PKD2)

Exclusion criteria

Exclusion criteria: ADPKD patients with genetic mutation of disease gene(PKD1,PKD2)

Design outcomes

Primary

Measure	Time frame
The Increase Rate of Total Kidney Volume	—

Secondary

Measure	Time frame
The Decrease rate of estimated Glomerular Filtration Rate	—

Contacts

Public ContactSatoru Muto

Juntendo University Hospital

s-muto@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026